The role of the endocannabinoid system in islet biology

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 2, 2011, Pages 153-158

  Doyle, Máire E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 arachidonoylglycerol; anandamide; beta cell; cannabinoid 1 receptor; insulin secretion; islet

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AM 6545; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; HEMOGLOBIN A1C; RIMONABANT; UNCLASSIFIED DRUG;

ANXIETY; ARTICLE; DEPRESSION; GLUCOSE TOLERANCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; SIDE EFFECT; SUICIDAL IDEATION;

ANIMALS; ENDOCANNABINOIDS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

EID: 79952439932     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32834455a8     Document Type: Article

References (41)

1. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202. (Pubitemid 34575709)
2. Di Marzo V, Bifulco M, De Petrocellis L The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3:771-784. (Pubitemid 39242829)
3. Nyiri G, Cserep C, Szabadits E, et al. CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippo-campal GABAergic axons. Neuroscience 2005; 136:811-822. (Pubitemid 41774726)
4. Bermudez-Silva FJ, Suarez J, Baixeras E, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008; 51:476-487.
5. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregula-tion of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91:3171-3180. (Pubitemid 44271774)
6. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008; 160:1-24.
7. Kunos G, Osei-Hyiaman D, Batkai S, et al. Should peripheral CB(1) canna-binoid receptors be selectively targeted for therapeutic gain? Trends Phar-macol Sci 2009; 30:1-7.
8. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3:745-755. (Pubitemid 37328813)
9. Derkinderen P, Valjent E, Toutant M, et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 2003; 23: 2371-2382. (Pubitemid 36368926)
10. Gomez del Pulgar T, Velasco G, Sanchez C, et al. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 2002; 363:183-188. (Pubitemid 34280625)
11. Motaghedi R, McGraw TE. The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. Obesity (Silver Spring) 2008; 16:1727-1734.
12. Ohno-Shosaku T, Hashimotodani Y, Maejima T, Kano M. Calcium signaling and synaptic modulation: regulation of endocannabinoid-mediated synaptic modulation by calcium. Cell Calcium 2005; 38:369-374. (Pubitemid 41283274)
13. Maejima T, Oka S, Hashimotodani Y, et al. Synaptically driven endocanna-binoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. J Neurosci 2005; 25:6826-6835. (Pubitemid 41023150)
14. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295:761-775. (Pubitemid 43244304)
15. Van Gaal L, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic riskfactors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008; 31 (Suppl 2):S229-S240.
16. Jo YH, Chen YJ, Chua SC Jr, et al. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 2005; 48:1055-1066. (Pubitemid 41814707)
17. Malcher-Lopes R, Di S, Marcheselli VS, et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocan-nabinoid release. J Neurosci 2006; 26:6643-6650. (Pubitemid 44318346)
18. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008; 31:2169-2176.
19. Scheen AJ, Paquot N. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Pract Res Clin Endocrinol Metab 2009; 23:103-116.
20. Eckardt K, Sell H, Taube A, et al. Cannabinoid type 1 receptors in human skelet al muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 2009; 52:664-674.
21. Moreira FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depres-sion. Best Pract Res Clin Endocrinol Metab 2009; 23:133-144.
22. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115:1298-1305. (Pubitemid 40629049)
23. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28:640-648. (Pubitemid 38491158)
24. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118:3160-3169.
25. Lindborg KA, Teachey MK, Jacob S, Henriksen EJ. Effects of in vitro antag-onism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skelet al muscle. Diabetes Obes Metab 2010; 12:722-730.
26. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR14171 6 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005; 29:183-187. (Pubitemid 40188413)
27. Charron MJ, Gorovits N, Laidlaw JS, et al. Use of GLUT-4 null mice to study skelet al muscle glucose uptake. Clin Exp Pharmacol Physiol 2005; 32:308-313. (Pubitemid 40586067)
28. Pagano C, Pilon C, Calcagno A, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007; 92:4810-4819. (Pubitemid 350223464)
29. Juan-Picó P, Fuentes E, Bermudez-Silva FJ, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006; 39:155-162. (Pubitemid 43013847)
30. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca(2+) oscillation in isletbeta-cellsviaCB1 receptors. Regul Pept 2008; 145:49-53. (Pubitemid 350296356)
31. Starowicz KM, Cristino L, Matias I, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet Obesity (Silver Spring) 2008; 16:553-565. (Pubitemid 351328005)
32. Tharp WG, Lee YH, Maple RL, Pratley RE. The cannabinoid CB1 receptor is expressed in pancreatic delta-cells. Biochem Biophys Res Commun 2008; 372:595-600.
33. Li C, Bowe JE, Jones PM, Persaud SJ. Expression and function of cannabinoid receptors in mouse islets. Islets 2010; 2:293-302.
34. Grimsey NL, Goodfellow CE, Scotter EL, et al. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! J Neurosci Methods 2008; 171:78-86.
35. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113:546-593. (Pubitemid 46365961)
36. Li C, Jones PM, Persaud SJ.Cannabinoid receptorsarecoupledtostimulation of insulin secretion from mouse MIN6 beta-cells. Cell Physiol Biochem 2010; 26:187-196.
37. Ni Q, Ganesan A, Aye-Han NN, et al. Signaling diversity of PKA achieved via a Ca(2+)-cAMP-PKA oscillatory circuit. Nat Chem Biol 2011; 7:34-40.
38. Dyachok O, Isakov Y, Sagetorp J, Tengholm A. Oscillations of cyclic AMP in hormone-stimulated insulin-secreting beta-cells. Nature 2006; 439:349-352. (Pubitemid 43128861)
39. Bermudez-Siva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006; 531:282-284. (Pubitemid 43202248)
40. Irwin N, Hunter K, Frizzell N, Flatt PR. Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice. Eur J Pharmacol 2008; 581:226-233.
41. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120:2953-2966.